Bioinformatics analysis of the expression and clinical significance of the NUP210 Gene in acute myeloid leukaemia

Figures & data

Figure 1 . NUP210 mRNA expression in patients with AML and healthy individuals

Figure 2. Subgroup analysis of NUP210 mRNA expression in patients with AML. (A) AML subtypes according to FAB classification; (B) sex; (C) age.

Table 1. Clinical characteristics of patients with AML in the NUP210-high and -low expression groups

Characteristics		NUP210-low	NUP210-high	P-value
WBC × 10^9/L (mean ± SD)		39.05 ± 51.24	37.21 ± 43.48	0.8144
PB blast counts (mean ± SD)		66.63 ± 20.51	64.05 ± 25.01	0.4974
BM blast counts (mean ± SD)		45.68 ± 31.3	31.71 ± 30.8	0.007447
Age (n)	18–39	11	14	0.265
	40–59	28	20
	≥60	34	39
Sex (n)	Male	32	48	0.01262
	Female	41	25
Ethnicity (n)	White	67	69	0.6667
	Black or African American	5	3
	Asian	1	0
	Not Available	0	1
FAB (n)	M0	12	3	0.004043
	M1	16	19
	M2	20	16
	M4	20	14
	M5	4	17
	M6	0	2
	M7	1	2
Karyotype (n)	Normal	39	42	0.4127
	inv(16)	6	2
	t(8;21)	5	2
	t(9;22)	1	0
	Complex	10	11
	Others	6	10
	Not Available	6	6
Risk (n)	Favourable	12	5	0.1926
	Intermediate	44	50
	Poor	17	18

Abbreviations: SD, standard deviation; WBC, white blood cell; PB, peripheral blood; BM, bone marrow; FAB, French-American-British classification.

Figure 3. Probability of survival for patients with AML in NUP210-high and NUP210-low expression groups. (A) All patients; (B) women; (C) men.

Table 2. Multivariate analyses of factors potentially affecting the overall survival of patients with AML.

Variables	P	HR	95% CI
Age	< 0.0001	1.0414	1.0236–1.0595
WBC	0.6048	1.0014	0.9960–1.0068
PB blasts	0.0668	1.0078	0.9995–1.0163
BM blasts	0.1363	1.0071	0.9978–1.0166
Sex	0.1675	0.7290	0.4654–1.1419
FAB	0.2675	1.0794	0.9430–1.2356
Risk	0.0397	0.6681	0.4549–0.9812
NUP210	0.0018	1.7707	1.2364–2.5358

Abbreviations: HR, hazard ratio; CI, confidence interval; WBC, white blood cell; PB, peripheral blood; BM, bone marrow; FAB, French-American-British classification.

Figure 4. AUC analysis to assess the prognostic value of NUP210 expression in AML. (A–C) ROC curves for 1-year (A), 3-year (B), and 5-year (C) survival of all patients with AML; (D–F) ROC curves for 1-year (D), 3-year (E), and 5-year (F) survival of female patients with AML.